These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29360666)

  • 21. Expression of class II major histocompatibility complex antigens (HLA-DR) and lymphocyte subset immunotyping in chronic pulmonary transplant rejection.
    Hasegawa S; Ockner DM; Ritter JH; Patterson GA; Trulock EP; Cooper JD; Wick MR
    Arch Pathol Lab Med; 1995 May; 119(5):432-9. PubMed ID: 7748071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
    Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
    J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome.
    SivaSai KS; Smith MA; Poindexter NJ; Sundaresan SR; Trulock EP; Lynch JP; Cooper JD; Patterson GA; Mohanakumar T
    Transplantation; 1999 Apr; 67(8):1094-8. PubMed ID: 10232557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome.
    Lu KC; Jaramillo A; Mendeloff EN; Huddleston CB; Sweet SC; Patterson GA; Mohanakumar T
    J Heart Lung Transplant; 2003 Jan; 22(1):35-43. PubMed ID: 12531411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.
    Burlingham WJ; Love RB; Jankowska-Gan E; Haynes LD; Xu Q; Bobadilla JL; Meyer KC; Hayney MS; Braun RK; Greenspan DS; Gopalakrishnan B; Cai J; Brand DD; Yoshida S; Cummings OW; Wilkes DS
    J Clin Invest; 2007 Nov; 117(11):3498-506. PubMed ID: 17965778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Autoimmune-Associated Single Nucleotide Polymorphism Within
    Budding K; van Setten J; van de Graaf EA; van Rossum OA; Kardol-Hoefnagel T; Kwakkel-van Erp JM; Oudijk ED; Hack CE; Otten HG
    Front Immunol; 2018; 9():3105. PubMed ID: 30705675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome.
    Reznik SI; Jaramillo A; SivaSai KS; Womer KL; Sayegh MH; Trulock EP; Patterson GA; Mohanakumar T
    Am J Transplant; 2001 Sep; 1(3):228-35. PubMed ID: 12102256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Exosomes with Distinct Properties during Chronic Lung Allograft Rejection.
    Gunasekaran M; Sharma M; Hachem R; Bremner R; Smith MA; Mohanakumar T
    J Immunol; 2018 Apr; 200(8):2535-2541. PubMed ID: 29491008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation.
    Morrell MR; Pilewski JM; Gries CJ; Pipeling MR; Crespo MM; Ensor CR; Yousem SA; D'Cunha J; Shigemura N; Bermudez CA; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2014 Dec; 33(12):1288-94. PubMed ID: 25443870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients?
    Hadjiliadis D; Davis RD; Palmer SM
    Chest; 2002 Oct; 122(4):1168-75. PubMed ID: 12377838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor factors are associated with bronchiolitis obliterans syndrome after lung transplantation.
    Hennessy SA; Hranjec T; Swenson BR; Kozower BD; Jones DR; Ailawadi G; Kron IL; Lau CL
    Ann Thorac Surg; 2010 May; 89(5):1555-62. PubMed ID: 20417777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation.
    Luckraz H; Sharples L; McNeil K; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 2003 Mar; 22(3):287-91. PubMed ID: 12633696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.
    Sundaresan S; Mohanakumar T; Smith MA; Trulock EP; Lynch J; Phelan D; Cooper JD; Patterson GA
    Transplantation; 1998 Mar; 65(5):648-53. PubMed ID: 9521198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients.
    Lyu DM; Grazia TJ; Benson AB; Cagle LR; Freed BM; Zamora MR
    Clin Transpl; 2012; ():237-46. PubMed ID: 23721028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch.
    Zou J; Duffy B; Slade M; Young AL; Steward N; Hachem R; Mohanakumar T
    Hum Immunol; 2017 Apr; 78(4):342-349. PubMed ID: 28267558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction.
    Girnita AL; Duquesnoy R; Yousem SA; Iacono AT; Corcoran TE; Buzoianu M; Johnson B; Spichty KJ; Dauber JH; Burckart G; Griffith BP; McCurry KR; Zeevi A
    Am J Transplant; 2005 Jan; 5(1):131-8. PubMed ID: 15636621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral immunity and complement effector mechanisms after lung transplantation.
    Budding K; van de Graaf EA; Otten HG
    Transpl Immunol; 2014 Oct; 31(4):260-5. PubMed ID: 25195091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of bronchiolitis obliterans syndrome despite blood chimerism in human lung transplant recipients.
    Calhoun R; SivaSai KS; Sundaresan S; Trulock EP; Lynch JP; Patterson GA; Cooper JD; Mohanakumar T
    Transpl Int; 1999; 12(6):439-46. PubMed ID: 10654356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: implications for donor lung allocation.
    Peltz M; Edwards LB; Jessen ME; Torres F; Meyer DM
    J Heart Lung Transplant; 2011 Apr; 30(4):426-34. PubMed ID: 21145259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
    Valentine VG; Gupta MR; Walker JE; Seoane L; Bonvillain RW; Lombard GA; Weill D; Dhillon GS
    J Heart Lung Transplant; 2009 Feb; 28(2):163-9. PubMed ID: 19201342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.